Myostatin Inhibitors Under research

Myostatin HMP

Also known as: Human Myostatin Propeptide, GDF-8 Propeptide

Human Myostatin Propeptide (Myostatin HMP) is the natural precursor molecule that regulates myostatin activity. Myostatin is secreted in an inactive form bound to its propeptide. Administering synthetic HMP generates an excess of propeptides in the blood that sequester mature myostatin, deactivating it with extremely high biological specificity. Unlike follistatin, it is exclusive to myostatin, without affecting other activins.

Mechanism of action

Circulating active myostatin recombines with the injected HMP, forming an inactive latent complex.
Being highly specific, it blocks GDF-8 without the risk of collateral effects on other TGF-β mediated body systems.

Uses & indications

Strength and mass development: Experimental use with no reproductive or organic impact.
Safe treatment of atrophies: Under active clinical investigation due to improved safety profile vs Follistatin.

Effects

Safe and progressive increase in lean muscle volume in in-vivo protocols. Virtually zero adverse effect profile in comparative preclinical trials.

Considerations & contraindications

Results are less explosive than FST-344, but much more sustainable and safe.
High cost of pure biotechnological synthesis.

Regulatory approval

Still in pre-clinical and experimental laboratory phases.

Dosage

Research suggests 1mg injections weekly or bi-weekly due to its long serum duration.

Storage

Lyophilized at -20°C.

Technical data

Regulatory status Under research

Molecular weight ~27.8 kDa

Half-life Prolongada (Días)

Administration routes Subcutánea o Intramuscular